-  INCLUSION CRITERIA:

        Patients must meet all the following criteria to be eligible for study enrolment:

          -  Diagnosis of advanced RCC associated with HLRCC (cohorts 1 & 3) or sporadic/non-HLRCC
             papillary RCC (cohort 2 & 4)

          -  Measurable disease outlined in RECIST 1.1

          -  No more than two prior regimens targeting the VEGF pathway; no prior bevacizumab
             therapy

          -  Age greater than or equal to 18 years.

          -  Performance status ECOG 0-2

          -  Patients must have normal organ and marrow function as defined below: WBC count
             greater than or equal to 3,000/microL, absolute neutrophil count greater than or equal
             to 1,500/microL, platelet count greater than or equal to 100,000/microL, serum
             creatinine greater than or equal to 2 times the upper limit of reference range or
             creatinine clearance greater than or equal to 30 ml/min, AST and ALT less than 2.5
             times the upper limit of reference range, total bilirubin less than 1.5 times the
             upper limit of reference range ( less than 3 x upper limit of reference range in
             patients with Gilbert s disease), alkaline phosphatase less than or equal to 2.5 times
             the upper limit of reference range (or less than than or equal to 5 times the upper
             limit of reference range if considered to be related to liver or bone metastases by
             the PI)

          -  Recovery from acute toxicity of prior treatment for RCC (to less than or equal to
             grade 1 the active version of CTCAE or to a level permitted under other sections of
             Inclusion/ Exclusion criteria).

          -  At least 4 weeks from completion of major surgery and a healed surgical incision

          -  Negative pregnancy test (within 7 days of enrolment) in women of childbearing
             potential

          -  No myocardial infarction, GI perforation/fistula, intraabdominal abscess,
             cerebrovascular accidents within six months prior to study entry

          -  No coagulopathy or bleeding diathesis

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Archival tissue block or unstained tumor tissue available for correlative studies

        EXCLUSION CRITERIA:

          -  Prior invasive malignancy of other histology, with the exception of adequately treated
             basal or squamous cell carcinoma of the skin, or any other malignancy for which the
             patient does not currently require treatment and/or has no evidence of disease for
             greater than or equal to 2 years.

          -  Patients with known brain metastases unless treated with an appropriate modality with
             no evidence of progression/recurrence for greater than 3 months

          -  Hypertension not controlled by medical therapy (resting systolic blood pressure
             greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg on at least two
             occasions over a 24 hour period despite optimal medical management).

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring intravenous antibiotics, symptomatic congestive heart failure (New
             York Heart Association grade III or greater), unstable angina pectoris, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          -  Serious, non-healing wound or ulcer; bone fracture within 3 months prior to study
             entry

          -  Patient known to be HIV-positive and requiring antiretroviral therapy (due to the risk
             of potential drug interactions)

          -  Concomitant therapy with potent inhibitors of CYP450 3A4 (e.g. ketoconazole, verapamil
             etc) or with potent CYP450 1A2 inhibitors (fluoroquinolone antibiotics including
             ciprofloxacin, levofloxacin, and norfloxacin; ticlodipine, cimetidine, amiodarone,etc.
             see Appendix C)

          -  Pregnant women are excluded from this study because bevacizumab and erlotinib are
             anti-cancer agents with the potential for teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with these agents, breastfeeding should be
             discontinued if the mother is treated on this study

          -  All men and women of childbearing potential must be willing to use effective
             contraception as determined by the principal investigator (including but not limited
             to abstinence, hormonal contraceptives (birth control pills, injections, or implants),
             intrauterine device (IUD), tubal ligation, vasectomy) from the time of enrolment to at
             least six months following the last dose of drug

          -  Any known hypersensitivity to bevacizumab, erlotinib or other excipients of these
             drugs

          -  Documented baseline proteinuria greater than 1000mg/day on 24 hour urine collection.
             Only patients with 1+ or greater proteinuria on UA and a spot urine protein:creatinine
             ratio of greater than 0.5 will undergo a 24 hour urine collection for quantitation of
             proteinuria.

          -  Left ventricular ejection fraction less than 40% as measured on transthoracic
             echocardiogram.

        INCLUSION OF WOMEN AND MINORITIES:

        Both men and women and members of all races and ethnic groups are eligible for this trial.